Aclaris Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 3, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Capitalization	364	326	265	74	1,050	890
Market Cap Growth	134.97%	22.88%	256.84%	-92.92%	17.97%	220.59%
Enterprise Value	220	161	95	-110	805	650
Last Close Price	3.05	3.01	2.48	1.05	15.75	14.54
PS Ratio	47.23	41.67	14.18	2.38	35.30	131.67
PB Ratio	3.57	3.16	1.71	0.47	5.32	4.51
P/TBV Ratio	3.59	3.16	1.71	0.47	5.51	4.68
EV/Sales Ratio	28.16	20.59	5.06	-	27.04	96.09
Debt / Equity Ratio	0.02	0.02	0.02	0.02	0.01	0.02
Net Debt / Equity Ratio	-1.45	-1.45	-1.29	-1.13	-1.15	-1.13
Net Debt / EBITDA Ratio	2.02	2.02	3.86	1.56	-	3.42
Net Debt / FCF Ratio	3.16	3.16	9.97	2.24	3.34	4.25
Asset Turnover	0.04	0.04	0.09	0.14	0.12	0.04
Quick Ratio	3.36	3.36	3.99	3.86	9.94	8.38
Current Ratio	3.36	3.36	3.99	4.16	10.56	8.94
Return on Equity (ROE)	-50.20%	-50.20%	-84.46%	-49.88%	-44.01%	-77.33%
Return on Assets (ROA)	-24.32%	-24.32%	-15.72%	-31.67%	-21.04%	-25.38%
Return on Capital Employed (ROCE)	-56.20%	-56.20%	-27.80%	-68.80%	-36.60%	-28.60%
Earnings Yield	-17.56%	-19.91%	-49.76%	-118.96%	-8.28%	-10.21%
FCF Yield	-12.78%	-14.48%	-7.61%	-107.07%	-6.49%	-5.89%
Buyback Yield / Dilution	-58.56%	-58.56%	-10.73%	-7.05%	-14.95%	-33.36%

Updated Feb 26, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q